Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation

Br J Haematol. 2021 Mar;192(6):e148-e151. doi: 10.1111/bjh.17365. Epub 2021 Feb 22.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Allografts
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cytarabine / administration & dosage
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Interleukin-2 / administration & dosage
  • Leukemia, Myeloid, Acute / diagnostic imaging
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / administration & dosage

Substances

  • Antineoplastic Agents, Immunological
  • IL2 protein, human
  • Interleukin-2
  • Recombinant Fusion Proteins
  • Cytarabine